.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Colorcon
US Army
Express Scripts
Chinese Patent Office
Accenture
Moodys
QuintilesIMS
Mallinckrodt

Generated: July 24, 2017

DrugPatentWatch Database Preview

RYTARY Drug Profile

« Back to Dashboard

What is the patent landscape for Rytary, and when can generic versions of Rytary launch?

Rytary is a drug marketed by Impax Labs Inc and is included in one NDA. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-three patent family members in thirteen countries.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.

Summary for Tradename: RYTARY

Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:RYTARY at DailyMed

Pharmacology for Tradename: RYTARY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-002Jan 7, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Impax Labs Inc
RYTARY
carbidopa; levodopa
CAPSULE, EXTENDED RELEASE;ORAL203312-004Jan 7, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: RYTARY

Drugname Dosage Strength RLD Submissiondate
carbidopa and levodopaExtended-release Capsules23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mgRytary6/24/2015
carbidopa and levodopaExtended-release Capsules61.25 mg/245 mgRytary6/10/2015

International Patent Family for Tradename: RYTARY

Country Document Number Estimated Expiration
Canada2711014► Subscribe
World Intellectual Property Organization (WIPO)2009085306► Subscribe
Japan6033373► Subscribe
Hong Kong1215386► Subscribe
South Korea101451564► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
AstraZeneca
Medtronic
Novartis
Moodys
Argus Health
Colorcon
Cipla
QuintilesIMS
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot